Efficacy and safety of ginkgo biloba extract combined with donepezil hydrochloride in the treatment of Chinese patients with vascular dementia: A systematic review meta-analysis

Liangyi Xiao, Jie Tang, Huizhong Tan, Yao Xie, Shiliang Wang, Le Xie, Dahua WuFrontiers in Pharmacology 2024 · DOI

Abstract

Objective: To conduct a meta-analysis of the effectiveness and safety of ginkgo biloba extract combined with donepezil hydrochloride vs. donepezil for the treatment of vascular dementia (VaD). Methods: Four English databases (PubMed, EMBASE, Web of Science, Cochrane Library) and four Chinese databases (CNKI, Wanfang, VIP, CBM) were searched for literature published up to September 2023. Randomized controlled trials (RCTs) were included and assessed for quality according to the Risk of Bias tool. Results: 15 RCTs involving 1,309 participants were analyzed. Combination therapy was superior to donepezil alone in total effective rate (RR 1.28), MMSE scores (MD 2.98), and Activity of Daily Living (ADL) scores (MD 10.11). Conclusion: Ginkgo biloba extract combined with donepezil significantly improves clinical outcomes and physiological markers in VaD patients, though more high-quality RCTs are needed to validate these results.

Introduction

Vascular Dementia (VaD) is the second most common form of dementia, caused by reduced blood flow to the brain. While acetylcholinesterase inhibitors like donepezil are the standard of care, their efficacy is often limited. Ginkgo biloba extract (GBE) has long been used in traditional medicine for its neuroprotective and circulation-enhancing properties. This paper provides a rigorous statistical analysis of whether combining GBE with Western medicine offers a synergistic advantage for Chinese patients.

Methods and Study Selection

The authors conducted a systematic review following PRISMA guidelines. They synthesized data from 15 randomized controlled trials (RCTs) involving 1,309 participants. The selection process involved screening 512 initial records to identify the most relevant clinical evidence.

PRISMA flowchart illustrating the systematic literature search and study selection process.

Study quality was evaluated using the Cochrane Risk of Bias (RoB 2.0) tool. The assessment focused on randomization processes, deviations from intended interventions, and missing outcome data to ensure the reliability of the meta-analysis results.

Assessment of risk of bias across the 15 included randomized controlled trials.

Key Insights and Results

The meta-analysis revealed that the combination of GBE and donepezil targets VaD through multiple pathways:

  • Cognitive and Functional Gains: The combination group was 28% more likely to show clinical improvement. Beyond test scores (MMSE), patients showed significant improvements in the Barthel Index (BI) and Activity of Daily Living (ADL) scales, indicating better management of daily tasks.
  • Physiological Improvements: GBE significantly reduced homocysteine (HCY) levels and blood viscosity. These biomarkers are closely associated with brain tissue damage, suggesting that GBE addresses underlying vascular issues that donepezil alone does not.
  • Safety Profile: A critical finding was the lack of significant difference in adverse events between the combination and monotherapy groups (RR = 1.00). This suggests that adding GBE does not introduce additional toxicity or dangerous drug-drug interactions.
  • Treatment Duration: Subgroup analysis indicated that longer treatment durations (12 weeks) yielded better functional improvements than 4-week courses, suggesting the neuroprotective effects of GBE are cumulative.

Limitations and Future Work

While the results are promising, the study notes several limitations. All included trials were conducted in China, which may limit generalizability to other ethnic groups. Additionally, high heterogeneity was observed in cognitive scores, likely due to varying GBE dosages and formulations (tablets vs. injections). The authors call for large-scale, multi-center, double-blind RCTs with standardized protocols to confirm these findings globally.

Summary updated

Abstract

<b>Objective:</b> To conduct a meta-analysis of the effectiveness and safety of ginkgo biloba extract combined with donepezil hydrochloride vs. donepezil for the treatment of vascular dementia (VaD). <b>Methods:</b> Four English databases (PubMed, EMBASE, Web of Science, Cochrane Library) and four Chinese databases [the China National Knowledge Infrastructure Wanfang DATA, the Chongqing VIP Database (VIP), China Biomedical Database (CBM)] were manually searched for literature published from dates of the inception of the databases to September 2023. The randomized controlled trials (RCTs) of ginkgo biloba extract with donepezil hydrochloride vs. donepezil for the treatment of VaD were included. Relevant literature was screened, and the data in the included studies were extracted for quality assessment according to the Risk of bias tool. <b>Results:</b> A total of 1,309 participants were enrolled in the 15 RCTs. Of these, 656 participants were in the experimental group (ginkgo biloba extract combined with donepezil) and 653 participants were in the control group (donepezil).The results showed that combination therapy was superior to donepezil alone, and there were statistically significant differences in several outcomes including RR in change for total effective rate (1.28, 95% confidence intervals 1.20, 1.38, <i>p</i> < 0.001), MD in change for Mini-Mental State Examination score (2.98, 95%CI 2.31, 3.65, <i>p</i> < 0.001), Barthel Index score (8.55,95%CI 1.11, 15.99, <i>p</i> = 0.024), Activity of Daily Living Scale (ADL)score (10.11,95% CI 7.16,13.07,<i>p</i> < 0.001). <b>Conclusion:</b> Ginkgo biloba extract combined with donepezil dramatically improved the total effective rate, MMSE, BI and ADL scores, and decreased homocysteine (HCY), plasma viscosity (PV), whole blood viscosity at high cut (BVH) and whole blood viscosity at low cut (BVL) in VaD patients, while the effect on mean flow velocity and pulse index (PI) of middle cerebral artery (MCA) is not obvious. However, more relevant high-quality RCTs are needed to validate these results. <b>Systematic Review Registration:</b> Identifier CRD42023474678.
BibTeX
@inproceedings{xiao2024efficacy,
  author = {Liangyi Xiao and Jie Tang and Huizhong Tan and Yao Xie and Shiliang Wang and Le Xie and Dahua Wu},
  title = {{Efficacy and safety of ginkgo biloba extract combined with donepezil hydrochloride in the treatment of Chinese patients with vascular dementia: A systematic review meta-analysis}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2024.1374482},
}
Figure